{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:37:33Z","timestamp":1782506253371,"version":"3.54.5"},"reference-count":277,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Metastatic bone disease is a common and devastating complication to cancer, confounding treatments and recovery efforts and presenting a significant barrier to de-escalating the adverse outcomes associated with disease progression. Despite significant advances in the field, bone metastases remain presently incurable and contribute heavily to cancer-associated morbidity and mortality. Mechanisms associated with metastatic bone disease perpetuation and paralleled disruption of bone remodeling are highlighted to convey how they provide the foundation for therapeutic targets to stem disease escalation. The focus of this review aims to describe the preclinical modeling and diagnostic evaluation of metastatic bone disease as well as discuss the range of therapeutic modalities used clinically and how they may impact skeletal tissue.<\/jats:p>","DOI":"10.3390\/cells11081309","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T21:15:35Z","timestamp":1649798135000},"page":"1309","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Translational Strategies to Target Metastatic Bone Disease"],"prefix":"10.3390","volume":"11","author":[{"given":"Gabriel M.","family":"Pagnotti","sequence":"first","affiliation":[{"name":"Department of Endocrine, Neoplasia and Hormonal Disorders, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trupti","family":"Trivedi","sequence":"additional","affiliation":[{"name":"Department of Endocrine, Neoplasia and Hormonal Disorders, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid S.","family":"Mohammad","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Genetics, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1245\/s10434-014-4010-1","article-title":"A Promise to Our Patients with Metastatic Bone Disease","volume":"21","author":"Randall","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/1758834014521110","article-title":"Bone and brain metastasis in lung cancer: Recent advances in therapeutic strategies","volume":"6","author":"Passaro","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4103\/0976-3147.131661","article-title":"Spinal cord compression as initial presentation of metastatic occult follicular thyroid carcinoma","volume":"5","author":"Khan","year":"2014","journal-title":"J. Neurosci. Rural Pract."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer","volume":"55","author":"Coleman","year":"1987","journal-title":"Br. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12885-017-3922-0","article-title":"Incidence of bone metastases in patients with solid tumors: Analysis of oncology electronic medical records in the United States","volume":"18","author":"Hernandez","year":"2018","journal-title":"BMC Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: A fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/pcan.2016.62","article-title":"Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: Data from PREVAIL and AFFIRM trials","volume":"20","author":"Saad","year":"2017","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3747\/co.19.1011","article-title":"Bone-Targeted Agents and Skeletal-Related Events in Breast Cancer Patients with Bone Metastases: The State of the Art","volume":"19","author":"Clemons","year":"2012","journal-title":"Curr. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S1470-2045(08)70201-8","article-title":"The \u201cseed and soil\u201d hypothesis revisited","volume":"9","author":"Fidler","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"28418","DOI":"10.18632\/oncotarget.16084","article-title":"Circulating tumor cells promote the metastatic colonization of disseminated carcinoma cells by inducing systemic inflammation","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","article-title":"The Distribution of Secondary Growths in Cancer of The Breast","volume":"133","author":"Paget","year":"1889","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature17038","article-title":"Metastatic colonization by circulating tumour cells","volume":"529","author":"Obenauf","year":"2016","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of Bone Metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10555-007-9103-x","article-title":"A \u201cclass action\u201d against the microenvironment: Do cancer cells cooperate in metastasis?","volume":"27","author":"Bidard","year":"2008","journal-title":"Cancer Metastasis Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1546::AID-CNCR4>3.0.CO;2-I","article-title":"Mechanisms of bone metastasis","volume":"80","author":"Mundy","year":"1997","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S1470-2045(09)70088-9","article-title":"Imaging bone metastases in breast cancer: Techniques and recommendations for diagnosis","volume":"10","author":"Costelloe","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/1758834009358417","article-title":"Renal cell carcinoma bone metastases: Clinical advances","volume":"2","author":"Sahi","year":"2010","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrg2101","article-title":"Genetic determinants of cancer metastasis","volume":"8","author":"Nguyen","year":"2007","journal-title":"Nat. Rev. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jbo.2016.03.007","article-title":"The role of osteoblasts in bone metastasis","volume":"5","author":"Ottewell","year":"2016","journal-title":"J. Bone Oncol."},{"key":"ref_20","first-page":"1567","article-title":"The role of the osteoblast in bone metastasis","volume":"19","author":"Guise","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"147S","DOI":"10.1378\/chest.123.1_suppl.147S","article-title":"The noninvasive staging of non-small cell lung cancer: The guidelines","volume":"123","author":"Silvestri","year":"2003","journal-title":"Chest"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/1903757","article-title":"Sclerotic Bone Metastasis in Pulmonary Adenocarcinoma","volume":"2018","author":"Hammamy","year":"2018","journal-title":"Case Rep. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4329\/wjr.v7.i8.202","article-title":"Imaging of bone metastasis: An update","volume":"7","author":"Carty","year":"2015","journal-title":"World J. Radiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100282","DOI":"10.1016\/j.jbo.2020.100282","article-title":"Bone metastases in thyroid cancer","volume":"21","author":"Bible","year":"2020","journal-title":"J. Bone Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1097\/01.blo.0000093847.72468.2f","article-title":"Molecular Mechanisms of Bone Metastasis and Therapeutic Implications","volume":"415","author":"Guise","year":"2003","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/jbmr.262","article-title":"The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: Is a revision needed?","volume":"26","author":"Khosla","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(10)60355-8","article-title":"Primary ovarian insufficiency","volume":"376","author":"Devroey","year":"2010","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF01806673","article-title":"Breast cancer survivors: Psychosocial concerns and quality of life","volume":"38","author":"Ganz","year":"1996","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/bjc.1990.58","article-title":"Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer","volume":"61","author":"Bruning","year":"1990","journal-title":"Br. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/annonc\/3.suppl_4.S105","article-title":"Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP\/ABVD chemotherapy for Hodgkin\u2019s disease","volume":"3","author":"Kreuser","year":"1992","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/SPC.0000000000000382","article-title":"Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition","volume":"12","author":"Pin","year":"2018","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/nature04186","article-title":"VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche","volume":"438","author":"Kaplan","year":"2005","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1158\/1078-0432.CCR-16-0028","article-title":"Cancer Tills the Premetastatic Field: Mechanistic Basis and Clinical Implications","volume":"22","author":"Chin","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ccell.2016.09.011","article-title":"Characteristics and Significance of the Pre-metastatic Niche","volume":"30","author":"Liu","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1593\/neo.09822","article-title":"CD44v6 Dependence of Premetastatic Niche Preparation by Exosomes","volume":"11","author":"Jung","year":"2009","journal-title":"Neoplasia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ncb3169","article-title":"Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver","volume":"17","author":"Aiello","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrc.2016.44","article-title":"Bone metastasis: The importance of the neighbourhood","volume":"16","author":"Croucher","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccell.2014.11.017","article-title":"The Osteogenic Niche Promotes Early-Stage Bone Colonization of Disseminated Breast Cancer Cells","volume":"27","author":"Wang","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cmet.2018.12.014","article-title":"A \u201cConnexin\u201d Responsible for the Fatal Attraction of Cancer to Bone","volume":"29","author":"Waning","year":"2019","journal-title":"Cell Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc704","article-title":"Hypoxia\u2014A key regulatory factor in tumour growth","volume":"2","author":"Harris","year":"2002","journal-title":"Nat. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrc1367","article-title":"Exploiting tumour hypoxia in cancer treatment","volume":"4","author":"Brown","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S8756-3282(02)00685-3","article-title":"Parathyroid hormone-related protein (PTHrP)-(1-139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo","volume":"30","author":"Guise","year":"2002","journal-title":"Bone"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12018-014-9160-y","article-title":"The Role of PTHrP in Skeletal Metastases and Hypercalcemia of Malignancy","volume":"12","author":"Wright","year":"2014","journal-title":"Clin. Rev. Bone Miner. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1572::AID-CNCR7>3.0.CO;2-M","article-title":"Parathyroid hormone-related protein and bone metastases","volume":"80","author":"Guise","year":"1997","journal-title":"Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/nm.1943","article-title":"Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis","volume":"15","author":"Korpal","year":"2009","journal-title":"Nat. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/nm.3961","article-title":"Excess TGF-beta mediates muscle weakness associated with bone metastases in mice","volume":"21","author":"Waning","year":"2015","journal-title":"Nat. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1517\/13543784.2012.679928","article-title":"Progress in the treatment of bone metastases in cancer patients","volume":"21","author":"Pankowska","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_48","first-page":"293","article-title":"Studies on prostatic cancer\u2014I The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1590\/S1677-55382011000300008","article-title":"Clamp ablation of the testes compared to bilateral orchiectomy as androgen deprivation therapy for advanced prostate cancer","volume":"37","author":"Zarrabi","year":"2011","journal-title":"Int. Braz. J. Urol."},{"key":"ref_51","unstructured":"(1967). Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-operative Urological Research Group. Surg. Gynecol. Obstet., 124, 1011\u20131017."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.2018.77.9827","article-title":"Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment","volume":"36","author":"Attard","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_54","first-page":"4315","article-title":"A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy","volume":"61","author":"Gregory","year":"2001","journal-title":"Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJMra022219","article-title":"Selective Estrogen-Receptor Modulators\u2014Mechanisms of Action and Application to Clinical Practice","volume":"348","author":"Riggs","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-015-0194-5","article-title":"Palbociclib: A first-in-class CDK4\/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer","volume":"8","author":"Lu","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ctrv.2017.09.003","article-title":"CDK4\/6 inhibition in early and metastatic breast cancer: A review","volume":"60","author":"Kuijpers","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_58","unstructured":"(2022, January 18). Food and Drug Administration FDA Approves Ibrance for Post-Menopausal Women with Advanced Breast Cancer, Available online: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm432871.htm."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"8406","DOI":"10.18632\/oncotarget.14139","article-title":"Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo","volume":"8","author":"Wright","year":"2016","journal-title":"Oncotarget"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1177\/0300985815586223","article-title":"Animal Models of Bone Metastasis","volume":"52","author":"Simmons","year":"2015","journal-title":"Vet. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/bonekey.2016.31","article-title":"Murine models of breast cancer bone metastasis","volume":"5","author":"Wright","year":"2016","journal-title":"BoneKEy Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1534\/g3.117.039909","article-title":"Whole-Genome Sequence of the Metastatic PC3 and LNCaP Human Prostate Cancer Cell Lines","volume":"7","author":"Seim","year":"2017","journal-title":"G3"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10549-018-4924-6","article-title":"Impact of primary breast cancer therapy on energetic capacity and body composition","volume":"172","author":"Ballinger","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"E506","DOI":"10.1152\/ajpendo.00058.2006","article-title":"Continuous testosterone administration prevents skeletal muscle atrophy and enhances resistance to fatigue in orchidectomized male mice","volume":"291","author":"Axell","year":"2006","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/cncr.11150","article-title":"Animal models of bone metastasis","volume":"97","author":"Rosol","year":"2003","journal-title":"Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1148\/102.3.701","article-title":"99mTc-Labeled Polyphosphate as a Skeletal Imaging Agent","volume":"102","author":"Subramanian","year":"1972","journal-title":"Radiology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/os.12334","article-title":"Spinal Metastatic Disease: A Review of the Role of the Multidisciplinary Team","volume":"9","author":"Curtin","year":"2017","journal-title":"Orthop. Surg."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3389\/fendo.2018.00518","article-title":"Multimodal Treatment of Bone Metastasis\u2014A Surgical Perspective","volume":"9","author":"Soeharno","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-87121-1","article-title":"Comprehensive surgical treatment strategy for spinal metastases","volume":"11","author":"Wagner","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_70","first-page":"482","article-title":"A scoring system for preoperative evaluation of the prognosis of metastatic spine tumor (a preliminary report)","volume":"63","author":"Tokuhashi","year":"1989","journal-title":"Nihon Seikeigeka Gakkai Zasshi"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1097\/01.brs.0000180401.06919.a5","article-title":"A Revised Scoring System for Preoperative Evaluation of Metastatic Spine Tumor Prognosis","volume":"30","author":"Tokuhashi","year":"2005","journal-title":"Spine"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"E1339","DOI":"10.1097\/BRS.0b013e3181e574f5","article-title":"Preoperative Scoring Systems and Prognostic Factors for Patients With Spinal Metastases From Hepatocellular Carcinoma","volume":"35","author":"Chen","year":"2010","journal-title":"Spine"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/00007632-200102010-00016","article-title":"Surgical Strategy for Spinal Metastases","volume":"26","author":"Tomita","year":"2001","journal-title":"Spine"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1097\/00007632-200205150-00027","article-title":"Surgical strategy for spinal metastases","volume":"27","author":"Bauer","year":"2002","journal-title":"Spine"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/17453679508995508","article-title":"Survival after surgery for spinal and extremity metastases: Prognostication in 241 patients","volume":"66","author":"Bauer","year":"1995","journal-title":"Acta Orthop. Scand."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/cncr.23150","article-title":"The first score predicting overall survival in patients with metastatic spinal cord compression","volume":"112","author":"Rades","year":"2007","journal-title":"Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/s00066-012-0106-3","article-title":"A survival score for patients with metastatic spinal cord compression from prostate cancer","volume":"188","author":"Rades","year":"2012","journal-title":"Strahlenther. Und Onkol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00066-012-0230-0","article-title":"A validated survival score for breast cancer patients with metastatic spinal cord compression","volume":"189","author":"Rades","year":"2012","journal-title":"Strahlenther. Und Onkol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00066-012-0130-3","article-title":"Metastatic spinal cord compression in patients with cancer of unknown primary","volume":"188","author":"Douglas","year":"2012","journal-title":"Strahlenther. Und Onkol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1302\/0301-620X.87B5.15185","article-title":"Prognostic factors and a scoring system for patients with skeletal metastasis","volume":"87b","author":"Katagiri","year":"2005","journal-title":"J. Bone Jt. Surg. Br."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0140-6736(05)66954-1","article-title":"Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: A randomised trial","volume":"366","author":"Patchell","year":"2005","journal-title":"Lancet"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00007632-200104010-00025","article-title":"Spinal Radiation Before Surgical Decompression Adversely Affects Outcomes of Surgery for Symptomatic Metastatic Spinal Cord Compression","volume":"26","author":"Ghogawala","year":"2001","journal-title":"Spine"},{"key":"ref_83","first-page":"1","article-title":"The Surgical Treatment of Pelvic Bone Metastases","volume":"2015","author":"Capanna","year":"2015","journal-title":"Adv. Orthop."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12957-016-0836-2","article-title":"Intramedullary nailing has sufficient durability for metastatic femoral fractures","volume":"14","author":"Tanaka","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.1016\/j.suronc.2010.09.001","article-title":"Minimally invasive surgery of humeral metastasis using flexible nails and cement in high-risk patients with advanced cancer","volume":"20","author":"Kim","year":"2011","journal-title":"Surg. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.suronc.2014.03.006","article-title":"Palliative percutaneous stabilization of lower extremity for bone metastasis using flexible nails and bone cement","volume":"23","author":"Kim","year":"2014","journal-title":"Surg. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0360-3016(94)E0310-G","article-title":"Role of postoperative radiation therapy after stabilization of fractures caused by metastatic disease","volume":"31","author":"Townsend","year":"1995","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Miller, B.J., Soni, E.E.C., Gibbs, C.P., and Scarborough, M.T. (2011). Intramedullary Nails for Long Bone Metastases: Why Do They Fail?. Orthopedics, 34.","DOI":"10.3928\/01477447-20110228-12"},{"key":"ref_90","first-page":"256","article-title":"Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures","volume":"1989","author":"Mirels","year":"1989","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11999-015-4453-0","article-title":"CT-based Structural Rigidity Analysis Is More Accurate Than Mirels Scoring for Fracture Prediction in Metastatic Femoral Lesions","volume":"474","author":"Damron","year":"2016","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0167-8140(03)00232-9","article-title":"Simple radiographic parameter predicts fracturing in metastatic femoral bone lesions: Results from a randomised trial","volume":"69","author":"Kroon","year":"2003","journal-title":"Radiother. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1089\/jpm.2014.9395","article-title":"ACR Appropriateness Criteria((R)) Non-Spine Bone Metastases","volume":"18","author":"Kim","year":"2015","journal-title":"J. Palliat. Med."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"British Association of Surgical Oncology Guidelines (1999). The management of metastatic bone disease in the United Kingdom. The Breast Specialty Group of the British Association of Surgical Oncology. Eur. J. Surg. Oncol., 25, 3\u201323.","DOI":"10.1053\/ejso.1998.0593"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e000037","DOI":"10.1136\/esmoopen-2016-000037","article-title":"Diagnosis and treatment of bone metastasis: Comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology","volume":"1","author":"Shibata","year":"2016","journal-title":"ESMO Open"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.clon.2009.04.002","article-title":"Advanced Breast Cancer: Diagnosis and Treatment. National Institute for Health and Clinical Excellence Guideline 2009\u2014A Solid Basis for Good Clinical Practice","volume":"21","author":"Murray","year":"2009","journal-title":"Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.prro.2016.08.001","article-title":"Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline","volume":"7","author":"Lutz","year":"2017","journal-title":"Pr. Radiat. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00264-022-05304-5","article-title":"Jig-assisted modified Harrington reconstruction for metastatic bone destruction of the acetabulum","volume":"46","author":"Rajasekaran","year":"2022","journal-title":"Int. Orthop."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/01.blo.0000179735.37089.c2","article-title":"Endoprosthetic reconstructions: Results of long-term followup of 139 patients","volume":"438","author":"Torbert","year":"2005","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00264-003-0429-x","article-title":"Risk of amputation following limb salvage surgery with endoprosthetic replacement, in a consecutive series of 1261 patients","volume":"27","author":"Jeys","year":"2003","journal-title":"Int. Orthop."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/jamaoncol.2021.6628","article-title":"Comparison of Prophylactic Intravenous Antibiotic Regimens After Endoprosthetic Reconstruction for Lower Extremity Bone Tumors A Randomized Clinical Trial","volume":"8","author":"Ghert","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/BLO.0b013e3180619533","article-title":"Disease- and Recurrence-free Survival after Surgical Resection of Solitary Bone Metastases of the Pelvis","volume":"459","author":"Yasko","year":"2007","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_103","first-page":"191","article-title":"Surgical treatment of bone metastases in patients with breast cancer","volume":"2002","author":"Lenz","year":"2002","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"vi37","DOI":"10.1093\/rheumatology\/kes283","article-title":"Overview of safety of non-biologic and biologic DMARDs","volume":"51","author":"Ruderman","year":"2012","journal-title":"Rheumatology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/ar3352","article-title":"Treating rheumatic patients with a malignancy","volume":"13","author":"Elandt","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/1097-0142(197306)31:6<1367::AID-CNCR2820310611>3.0.CO;2-6","article-title":"Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy","volume":"31","author":"Jaffe","year":"1973","journal-title":"Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/PL00011684","article-title":"Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with bone metastasis","volume":"3","author":"Hironaka","year":"2000","journal-title":"Gastric Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10147-007-0750-2","article-title":"Gastric phenotype signet-ring cell carcinoma of the stomach with multiple bone metastases effectively treated with sequential methotrexate and 5-fluorouracil","volume":"13","author":"Mizoshita","year":"2008","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.bone.2007.07.021","article-title":"Cellular mechanisms for methotrexate chemotherapy-induced bone growth defects","volume":"41","author":"Xian","year":"2007","journal-title":"Bone"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/jbmr.5650100608","article-title":"Effects of methotrexate on human osteoblasts in vitro: Modulation by 1,25-dihydroxyvitamin D3","volume":"10","author":"Scheven","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/ejso.2002.1337","article-title":"The effect of chemotherapy on the morphology of the growth plate and metaphysis of the growing skeleton","volume":"29","author":"Hartel","year":"2003","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.blo.0000073348.50837.f2","article-title":"Chemotherapy Decreases Epiphyseal Strength and Increases Bone Fracture Risk","volume":"413","author":"Verkerke","year":"2003","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/art.1780390317","article-title":"The effect of methotrexate on mouse bone cells in culture","volume":"39","author":"May","year":"1996","journal-title":"Arthritis Care Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1002\/jcp.23034","article-title":"The role of osteocyte apoptosis in cancer chemotherapy-induced bone loss","volume":"227","author":"Shandala","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study","volume":"26","author":"Berthold","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1172\/JCI132184","article-title":"Taxane resistance in prostate cancer is mediated by decreased drug-target engagement","volume":"130","author":"Gjyrezi","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_120","first-page":"105","article-title":"Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute","volume":"1986","author":"Hortobagyi","year":"1986","journal-title":"NCI Monogr. A Publ. Natl. Cancer Inst."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00774-008-0013-y","article-title":"Docetaxel inhibits bone resorption through suppression of osteoclast formation and function in different manners","volume":"27","author":"Takahashi","year":"2008","journal-title":"J. Bone Miner. Metab."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/91.19.1616","article-title":"Chemotherapy-Induced Anemia in Adults: Incidence and Treatment","volume":"91","author":"Groopman","year":"1999","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.apsb.2020.06.006","article-title":"Bone-seeking nanoplatform co-delivering cisplatin and zoledronate for synergistic therapy of breast cancer bone metastasis and bone resorption","volume":"10","author":"Huang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4161\/cc.4.2.1414","article-title":"Proteasome Inhibition in the Treatment of Cancer","volume":"4","author":"Richardson","year":"2004","journal-title":"Cell Cycle"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_126","first-page":"508","article-title":"Velcade\u00ae: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy","volume":"8","author":"Kane","year":"2003","journal-title":"Oncology"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1172\/JCI16198","article-title":"Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro","volume":"111","author":"Garrett","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/annonc\/mdj131","article-title":"Bortezomib (VELCADE\u00ae) in metastatic breast cancer: Pharmacodynamics, biological effects, and prediction of clinical benefits","volume":"17","author":"Yang","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.1158\/1078-0432.CCR-09-3293","article-title":"A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes","volume":"16","author":"Jones","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/bonekey.2013.129","article-title":"Effects of proteasome inhibitors on bone cancer","volume":"2","author":"Terpos","year":"2013","journal-title":"BoneKEy Rep."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/sj.pcan.4500823","article-title":"Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases","volume":"8","author":"Whang","year":"2005","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3892\/ijo.2014.2545","article-title":"Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurf1 and Smurf2","volume":"45","author":"Wang","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/sj.leu.2404806","article-title":"Bortezomib inhibits human osteoclastogenesis","volume":"21","author":"Krebbel","year":"2007","journal-title":"Leukemia"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"8018","DOI":"10.1200\/JCO.2017.35.15_suppl.8018","article-title":"Carfilzomib-associated cardiovascular adverse events: A systematic review and meta-analysis","volume":"35","author":"Waxman","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: Mechanism of Action and Role in Clinical Practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(87)92555-4","article-title":"Reduced Morbidity from Skeletal Metastases in Breast-Cancer Patients during Long-Term Bisphosphonate (Apd) Treatment","volume":"330","author":"Bijvoet","year":"1987","journal-title":"Lancet"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1330.e13","DOI":"10.1016\/j.cell.2021.03.010","article-title":"Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption","volume":"184","author":"McDonald","year":"2021","journal-title":"Cell"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in Postmenopausal Women with Low Bone Mineral Density","volume":"354","author":"McClung","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: An international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/bonekey.2014.14","article-title":"Targeting RANKL in metastasis","volume":"3","author":"Dougall","year":"2014","journal-title":"BoneKEy Rep."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr2769","article-title":"Anti-tumour activity of bisphosphonates in preclinical models of breast cancer","volume":"12","author":"Holen","year":"2010","journal-title":"Breast Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab Compared with Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ejca.2015.04.017","article-title":"The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease","volume":"51","author":"Diel","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.2018.36.15_suppl.501","article-title":"Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study","volume":"36","author":"Coleman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/pbc.25393","article-title":"Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone","volume":"62","author":"Gossai","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","article-title":"Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics","volume":"27","author":"Zysset","year":"2016","journal-title":"Osteoporos Int."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3389\/fped.2020.00515","article-title":"Case Report: Safety and Efficacy of Denosumab in Four Children with Noonan Syndrome with Multiple Giant Cell Lesions of the Jaw","volume":"8","author":"Ferriero","year":"2020","journal-title":"Front. Pediatr."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1210\/jc.2017-02025","article-title":"Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated with Denosumab for Giant Cell Tumor of Bone","volume":"103","author":"Uday","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1210\/endo.138.11.5505","article-title":"The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats","volume":"138","author":"Dobnig","year":"1997","journal-title":"Endocrinology"},{"key":"ref_151","first-page":"e1300","article-title":"Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis","volume":"9","author":"Tella","year":"2017","journal-title":"Cureus"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/bcp.13766","article-title":"Osteoanabolic and dual action drugs","volume":"85","author":"Tabacco","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"FASEB J."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1172\/jci.insight.125543","article-title":"Sclerostin inhibition alleviates breast cancer\u2013induced bone metastases and muscle weakness","volume":"4","author":"Hesse","year":"2019","journal-title":"JCI Insight"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.yrtph.2016.08.010","article-title":"Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study","volume":"81","author":"Chouinard","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/jbmr.4001","article-title":"Serious Adverse Events with Romosozumab Use in Japanese Patients: Need for Clear Formulation of Contraindications Worldwide","volume":"35","author":"Kawaguchi","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"13909","DOI":"10.1073\/pnas.0506517102","article-title":"Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway","volume":"102","author":"Kang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Trivedi, T., Pagnotti, G.M., Guise, T.A., and Mohammad, K.S. (2021). The Role of TGF-beta in Bone Metastases. Biomolecules, 11.","DOI":"10.3390\/biom11111643"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1073\/pnas.80.12.3676","article-title":"Purification and Initial Characterization of a Type-Beta Transforming Growth-Factor from Human-Placenta","volume":"80","author":"Frolik","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/cr.2008.316","article-title":"Roles of TGFbeta in metastasis","volume":"19","author":"Padua","year":"2009","journal-title":"Cell. Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1349-7006.2007.00690.x","article-title":"Transforming growth factor beta derived from bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone microenvironment","volume":"99","author":"Sato","year":"2008","journal-title":"Cancer Sci."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","article-title":"TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance","volume":"8","author":"Thomas","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/bonekey.2012.96","article-title":"The role of TGF-beta in bone metastasis: Novel therapeutic perspectives","volume":"1","author":"Buijs","year":"2012","journal-title":"Bonekey Rep."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0092-8674(03)00432-X","article-title":"Mechanisms of TGF-beta signaling from cell membrane to the nucleus","volume":"113","author":"Shi","year":"2003","journal-title":"Cell"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Yamaoka, T., Kusumoto, S., Ando, K., Ohba, M., and Ohmori, T. (2018). Receptor Tyrosine Kinase-Targeted Cancer Therapy. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113491"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"96","DOI":"10.5603\/NMR.2011.00023","article-title":"Radioisotope therapy of bone metastases","volume":"14","year":"2011","journal-title":"Nucl. Med. Rev."},{"key":"ref_168","first-page":"3120","article-title":"Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model","volume":"62","author":"Henriksen","year":"2002","journal-title":"Cancer Res."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3181\/00379727-46-11899","article-title":"Biological Investigations with Radioactive Calcium and Strontium","volume":"46","author":"Pecher","year":"1941","journal-title":"Exp. Biol. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"328","DOI":"10.4149\/neo_2013_044","article-title":"A prospective randomized trial: A comparison of the analgesic effect and toxicity of 153Sm radioisotope treatment in monotherapy and combined therapy including local external beam radiotherapy (EBRT) among metastatic castrate resistance prostate cancer (mCRPC) patients with painful bone metastases","volume":"60","author":"Baczyk","year":"2013","journal-title":"Neoplasma"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1158\/1078-0432.CCR-16-2955","article-title":"Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models","volume":"23","author":"Suominen","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10549-014-2939-1","article-title":"A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease","volume":"145","author":"Coleman","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1628::AID-CNCR13>3.0.CO;2-1","article-title":"Radiation for bone metastases: Conventional techniques and the role of systemic radiopharmaceuticals","volume":"80","author":"Janjan","year":"1997","journal-title":"Cancer"},{"key":"ref_175","first-page":"114","article-title":"External beam radiotherapy and bone metastases","volume":"3","author":"Johnstone","year":"2014","journal-title":"Ann. Palliat. Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s13063-015-0761-7","article-title":"High-dose single-fraction IMRT versus fractionated external beam radiotherapy for patients with spinal bone metastases: Study protocol for a randomized controlled trial","volume":"16","author":"Rief","year":"2015","journal-title":"Trials"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11523-015-0379-4","article-title":"HPMA Copolymer-Conjugated Pirarubicin in Multimodal Treatment of a Patient with Stage IV Prostate Cancer and Extensive Lung and Bone Metastases","volume":"11","author":"Dozono","year":"2015","journal-title":"Target. Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Green, D.E., Adler, B.J., Chan, M.E., Lennon, J.J., Acerbo, A.S., Miller, L.M., and Rubin, C.T. (2013). Altered Composition of Bone as Triggered by Irradiation Facilitates the Rapid Erosion of the Matrix by Both Cellular and Physicochemical Processes. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0064952"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/jbmr.1505","article-title":"Devastation of adult stem cell pools by irradiation precedes collapse of trabecular bone quality and quantity","volume":"27","author":"Green","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/jbmr.2458","article-title":"Single-Limb Irradiation Induces Local and Systemic Bone Loss in a Murine Model","volume":"30","author":"Wright","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3109\/0284186X.2012.762995","article-title":"Hip fractures and pain following proton therapy for management of prostate cancer","volume":"52","author":"Valery","year":"2013","journal-title":"Acta Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/jnci\/95.3.222","article-title":"Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: Cost-utility analysis based on a randomized trial","volume":"95","author":"Steenland","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4103\/0973-1075.150178","article-title":"Comparison of single versus multiple fractions for palliative treatment of painful bone metastasis: First study from north west India","volume":"21","author":"Kapoor","year":"2015","journal-title":"Indian J. Palliat. Care"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.radonc.2006.02.007","article-title":"Patients with a favourable prognosis are equally palliated with single and multiple fraction radiotherapy: Results on survival in the Dutch Bone Metastasis Study","volume":"78","author":"Steenland","year":"2006","journal-title":"Radiother. Oncol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma\u2014A Preliminary-Report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.4049\/jimmunol.162.10.5813","article-title":"CTLA-4-Mediated inhibition of early events of T cell proliferation","volume":"162","author":"Brunner","year":"1999","journal-title":"J. Immunol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"E217","DOI":"10.12788\/jcso.0340","article-title":"Bone remodeling associated with CTLA-4 inhibition: An unreported side effect","volume":"15","author":"Rao","year":"2017","journal-title":"J. Community Support"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.2174\/138161210791034012","article-title":"The CXCR4\/SDF-1 Chemokine Axis: A Potential Therapeutic Target for Bone Metastases?","volume":"16","author":"Hirbe","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cytogfr.2009.11.009","article-title":"CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis","volume":"21","author":"Zhang","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00262-012-1202-z","article-title":"CAR T cells transform to trucks: Chimeric antigen receptor\u2013redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer","volume":"61","author":"Chmielewski","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/eji.200737524","article-title":"Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies","volume":"38","author":"Epel","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1177\/030006051204000608","article-title":"Mesothelin Promotes Invasion and Metastasis in Breast Cancer Cells","volume":"40","author":"Wang","year":"2012","journal-title":"J. Int. Med. Res."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-019-0169-8","article-title":"Mesothelin as a biomarker for targeted therapy","volume":"7","author":"Lv","year":"2019","journal-title":"Biomark. Res."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"104041","DOI":"10.1016\/j.cellimm.2020.104041","article-title":"Oncolytic adenovirus targeting TGF-beta enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer","volume":"348","author":"Li","year":"2020","journal-title":"Cell Immunol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1089\/hum.2010.018","article-title":"Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-beta receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model","volume":"21","author":"Hu","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"e002919","DOI":"10.1136\/jitc-2021-002919","article-title":"Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment","volume":"9","author":"Subudhi","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/436642a","article-title":"Tumour biology: Senescence in premalignant tumours","volume":"436","author":"Collado","year":"2005","journal-title":"Nature"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"107","DOI":"10.31557\/APJCP.2020.21.1.107","article-title":"Revealing the Reversal Effect of Galangal (Alpinia galanga L.) Extract Against Oxidative Stress in Metastatic Breast Cancer Cells and Normal Fibroblast Cells Intended as a Co- Chemotherapeutic and Anti-Ageing Agent","volume":"21","author":"Ahlina","year":"2020","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1146\/annurev-physiol-030212-183653","article-title":"Aging, Cellular Senescence, and Cancer","volume":"75","author":"Campisi","year":"2013","journal-title":"Annu. Rev. Physiol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrm2233","article-title":"Cellular senescence: When bad things happen to good cells","volume":"8","author":"Campisi","year":"2007","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nature12844","article-title":"Cell Biology. The beginning of the end","volume":"505","author":"Campisi","year":"2014","journal-title":"Nature"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.cell.2017.05.015","article-title":"Senescence in Health and Disease","volume":"169","author":"He","year":"2017","journal-title":"Cell"},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Copp\u00e9, J.-P., Patil, C.K., Rodier, F., Sun, Y., Mu\u00f1oz, D.P., Goldstein, J., Nelson, P.S., Desprez, P.-Y., and Campisi, J. (2008). Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor. PLoS Biol., 6.","DOI":"10.1371\/journal.pbio.0060301"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13578-020-00422-2","article-title":"Senolytic compounds control a distinct fate of androgen receptor agonist- and antagonist-induced cellular senescent LNCaP prostate cancer cells","volume":"10","author":"Pungsrinont","year":"2020","journal-title":"Cell Biosci."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5001\/omj.2016.19","article-title":"Hyperthermia: How Can It Be Used?","volume":"31","author":"Behrouzkia","year":"2016","journal-title":"Oman Med. J."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/02656739309061480","article-title":"Effects of hyperthermia on bone. II. Heating of bone in vivo and stimulation of bone growth","volume":"9","author":"Leon","year":"1993","journal-title":"Int. J. Hyperth."},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Van Rhoon, G.C., and van Holthe, J.M.L. (2018). Radiotherapy plus hyperthermia shows effectiveness in painful bony metastases\u2014Indicated only for selected patients with extended live expectancy and radiotherapy resistant tumor!. Ther. Radiol. Oncol., 2.","DOI":"10.21037\/tro.2018.09.01"},{"key":"ref_211","first-page":"3338","article-title":"Interaction of hyperthermia and radiation in murine cells: Hypoxia and acidosis in vitro, tumor subpopulations in vivo","volume":"49","author":"Herman","year":"1989","journal-title":"Cancer Res."},{"key":"ref_212","first-page":"1923","article-title":"Kinetic responses of murine sarcoma cells to radiation and hyperthermia in vivo and in vitro","volume":"36","author":"Kal","year":"1976","journal-title":"Cancer Res."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/07357908709032898","article-title":"The response of a solid tumor to X-irradiation as modified by dose rate, fractionation, and hyperthermia","volume":"5","author":"Baker","year":"1987","journal-title":"Cancer Investig."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(00)02059-6","article-title":"Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: A prospective, randomised, multicentre trial","volume":"355","author":"Hart","year":"2000","journal-title":"Lancet"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/jama.1981.03320210003001","article-title":"Radiotherapy plus hyperthermia equals progress against cancer","volume":"246","author":"Korcok","year":"1981","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10147-011-0217-3","article-title":"A novel hyperthermia treatment for bone metastases using magnetic materials","volume":"16","author":"Matsumine","year":"2011","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpainsymman.2003.10.003","article-title":"Pain management in cancer patients with bone metastases remains a challenge","volume":"27","author":"Yau","year":"2004","journal-title":"J. Pain Symptom Manag."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2214\/AJR.10.6029","article-title":"Palliation of painful metastatic disease involving bone with imaging-guided treatment: Comparison of patients\u2019 immediate response to radiofrequency ablation and cryoablation","volume":"197","author":"Thacker","year":"2011","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00256-007-0404-5","article-title":"Radiofrequency ablation of osseous metastases for the palliation of pain","volume":"37","author":"Thanos","year":"2008","journal-title":"Skelet. Radiol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1148\/rg.336125162","article-title":"MR Imaging-guided Focused Ultrasound for Treatment of Bone Metastasis","volume":"33","author":"Napoli","year":"2013","journal-title":"Radiographics"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.27793","article-title":"Percutaneous image-guided cryoablation of painful metastases involving bone: Multicenter trial","volume":"119","author":"Callstrom","year":"2013","journal-title":"Cancer"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"S322","DOI":"10.2214\/AJR.05.0265","article-title":"Saline-infused bipolar radiofrequency ablation of high-risk spinal and paraspinal neoplasms","volume":"186","author":"Buy","year":"2006","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40349-018-0117-3","article-title":"Focused ultrasound for the treatment of bone metastases: Effectiveness and feasibility","volume":"6","author":"Bertrand","year":"2018","journal-title":"J. Ther. Ultrasound"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1148\/radiol.2241011613","article-title":"Painful Metastases Involving Bone: Feasibility of Percutaneous CT- and US-guided Radio-frequency Ablation","volume":"224","author":"Callstrom","year":"2002","journal-title":"Radiology"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"e200101","DOI":"10.1148\/rycan.2021200101","article-title":"Cryoablation for Palliation of Painful Bone Metastases: The MOTION Multicenter Study","volume":"3","author":"Jennings","year":"2021","journal-title":"Radiol. Imaging Cancer"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.2147\/OTT.S195634","article-title":"Successful treatment with cryoablation in a patient with bone metastasis in the mid-shaft femur: A case report","volume":"12","author":"Kita","year":"2019","journal-title":"Onco Targets Ther."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1148\/radiol.2019181262","article-title":"Complications of Percutaneous Bone Tumor Cryoablation: A 10-year Experience","volume":"291","author":"Auloge","year":"2019","journal-title":"Radiology"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jbo.2017.04.002","article-title":"Postoperative complications with cryotherapy in bone tumors","volume":"7","author":"Chen","year":"2017","journal-title":"J. Bone Oncol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jpainsymman.2007.01.001","article-title":"Managing Metastatic Bone Pain: The Role of Bisphosphonates","volume":"33","author":"Gralow","year":"2007","journal-title":"J. Pain Symptom Manag."},{"key":"ref_230","first-page":"701","article-title":"Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases","volume":"88","author":"Beuzeboc","year":"2001","journal-title":"Bull. Cancer"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_232","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann. Oncol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000143219","article-title":"Opioids for Metastatic Bone Pain","volume":"74","author":"Hara","year":"2008","journal-title":"Oncology"},{"key":"ref_235","first-page":"15","article-title":"Cancer-related pain and its pharmacologic management in the patient with bone metastasis","volume":"4","author":"Slatkin","year":"2006","journal-title":"J. Support. Oncol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","article-title":"American Society of Clinical Oncology Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer","volume":"29","author":"Temin","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"284S","DOI":"10.1378\/chest.123.1_suppl.284S","article-title":"Lung cancer. Palliative care","volume":"123","author":"Kvale","year":"2003","journal-title":"Chest"},{"key":"ref_238","unstructured":"National Academies of Sciences (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research, National Academies of Sciences."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1002\/cncr.30879","article-title":"Cannabis Use Among Patients at a Comprehensive Cancer Center in a State with Legalized Medicinal and Recreational Use","volume":"123","author":"Pergam","year":"2017","journal-title":"Cancer"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fendo.2012.00136","article-title":"Role of cannabinoids in the regulation of bone remodeling","volume":"3","author":"Idris","year":"2012","journal-title":"Front. Endocrinol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.phrs.2017.02.023","article-title":"Emerging therapeutic targets in cancer induced bone disease: A focus on the peripheral type 2 cannabinoid receptor","volume":"119","author":"Marino","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"7383","DOI":"10.1158\/0008-5472.CAN-14-0934","article-title":"Combined Genome and Transcriptome Analysis of Single Disseminated Cancer Cells from Bone Marrow of Prostate Cancer Patients Reveals Unexpected Transcriptomes","volume":"74","author":"Braun","year":"2014","journal-title":"Cancer Res."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/OTT.S226770","article-title":"Transcriptome Analysis Reveals Key Genes and Pathways Associated with Metastasis in Breast Cancer","volume":"13","author":"Li","year":"2020","journal-title":"Onco Targets Ther."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/1476-4598-9-258","article-title":"Runx2 transcriptome of prostate cancer cells: Insights into invasiveness and bone metastasis","volume":"9","author":"Baniwal","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41391-020-00271-7","article-title":"Treatment of metastatic castration resistant prostate cancer with radium-223: A retrospective study at a US tertiary oncology center","volume":"24","author":"McKay","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_246","first-page":"1092","article-title":"Radium-223 in combination with paclitaxel in cancer patients with bone metastases: Safety results from an open-label, multicenter phase Ib study","volume":"46","author":"Geva","year":"2018","journal-title":"Eur. J. Pediatr."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/jbmr.377","article-title":"Effects of miR-335-5p in modulating osteogenic differ-entiation by specifically downregulating Wnt antagonist DKK1","volume":"26","author":"Zhang","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nature22306","article-title":"Surrogate Wnt agonists that phenocopy canonical Wnt and beta-catenin signalling","volume":"545","author":"Janda","year":"2017","journal-title":"Nature"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/bonekey.2012.101","article-title":"Wnt and Wnt inhibitors in bone metastasis","volume":"1","author":"Sottnik","year":"2012","journal-title":"BoneKEy Rep."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/jcb.20735","article-title":"Role of wnts in prostate cancer bone metastases","volume":"97","author":"Hall","year":"2006","journal-title":"J. Cell. Biochem."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","article-title":"Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma","volume":"114","author":"Fulciniti","year":"2009","journal-title":"Blood"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1038\/onc.2008.226","article-title":"Rational targeting of Notch signaling in cancer","volume":"27","author":"Rizzo","year":"2008","journal-title":"Oncogene"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2147\/OTT.S33766","article-title":"Gamma secretase inhibitors of Notch signaling","volume":"6","author":"Osipo","year":"2013","journal-title":"OncoTargets Ther."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.critrevonc.2013.05.015","article-title":"Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus","volume":"87","author":"Hadji","year":"2013","journal-title":"Crit. Rev. Oncol."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in Postmenopausal Hormone-Receptor\u2013Positive Advanced Breast Cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood-2009-08-237404","article-title":"Dysregulation of bone remodeling by imatinib mesylate","volume":"115","author":"Vandyke","year":"2010","journal-title":"Blood"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/sj.bjc.6605490","article-title":"Epidermal growth factor signalling and bone metastasis","volume":"102","author":"Lu","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1200\/JCO.2017.74.7352","article-title":"Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial","volume":"36","author":"Escudier","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.10.032","article-title":"Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma","volume":"126","author":"Donskov","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2006.08.002","article-title":"Mechanisms of Action of Bevacizumab as a Component of Therapy for Metastatic Colorectal Cancer","volume":"33","author":"Ellis","year":"2006","journal-title":"Semin. Oncol."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1177\/1078155218790338","article-title":"Potential role of rituximab in metastatic castrate-resistant prostate cancer","volume":"25","author":"Bindal","year":"2018","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: The complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/S1470-2045(18)30481-9","article-title":"Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): Final analysis of a double-blind, randomised, placebo-controlled phase 3 study","volume":"19","author":"Tabernero","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ctrv.2008.01.008","article-title":"Metastatic breast cancer: The role of pegylated liposomal doxorubicin after conventional anthracyclines","volume":"34","author":"Verma","year":"2008","journal-title":"Cancer Treat. Rev."},{"key":"ref_268","doi-asserted-by":"crossref","unstructured":"Adjei, I.M., Temples, M.N., Brown, S.B., and Sharma, B. (2018). Targeted Nanomedicine to Treat Bone Metastasis. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10040205"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: Clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat. Rev."},{"key":"ref_270","unstructured":"Yasir, M., Goyal, A., and Sonthalia, S. (2022). Corticosteroid Adverse Effects, StatPearls Publishing."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10555-006-9022-2","article-title":"The role of Wnts in bone metastases","volume":"25","author":"Hall","year":"2006","journal-title":"Cancer Metastasis Rev."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nrendo.2010.227","article-title":"Bone metastasis: Mechanisms and therapeutic opportunities","volume":"7","author":"Suva","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1152\/physrev.00012.2019","article-title":"Bone metastasis: Mechanisms, therapies, and biomarkers","volume":"101","author":"Coleman","year":"2021","journal-title":"Physiol. Rev."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The Diagnosis and Treatment of Prostate Cancer: A Review","volume":"317","author":"Litwin","year":"2017","journal-title":"JAMA"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jama.1969.03150230104014","article-title":"Treatment of primary and metastatic bone tumors by cryosurgery","volume":"207","author":"Marcove","year":"1969","journal-title":"J. Am. Med. Assoc."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0305-7372(10)70013-X","article-title":"New molecular targets in bone metastases","volume":"36","author":"Santini","year":"2010","journal-title":"Cancer Treat. Rev."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"7242","DOI":"10.1158\/1078-0432.CCR-06-0646","article-title":"Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and Response to Gefitinib and Other EGFR-Targeting Drugs","volume":"12","author":"Ono","year":"2006","journal-title":"Clin. Cancer Res."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/8\/1309\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:52:44Z","timestamp":1760136764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/8\/1309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":277,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["cells11081309"],"URL":"https:\/\/doi.org\/10.3390\/cells11081309","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,12]]}}}